Positive Biological Indicator in Steam Sterilization: A Practical Response Plan

A positive biological indicator (BI) result is one of the most important events in a steam sterilization monitoring program. It may indicate a sterilization process failure, but it may also result from incorrect indicator use, improper incubation or interpretation, equipment problems, or another procedural error. The response should therefore be immediate, documented, and systematic.

This article focuses on healthcare steam sterilizers and is intended for sterile processing, quality, infection prevention, and maintenance professionals. Local procedures, equipment instructions, applicable regulations, and validated sterilization processes should always govern the final decision.

Why a positive BI matters

A BI is designed to challenge the sterilization process with a defined population of resistant microorganisms. Its result is one part of a broader monitoring system that may also include physical cycle data, chemical indicators, load configuration controls, equipment maintenance, and record review. FDA describes process monitoring as including activities such as biological indicator testing, chemical indicator testing, process-record review, and control of critical parameters. [1]

A positive BI should not be treated as an isolated color-change event. The result must be interpreted together with the cycle printout or electronic record, the load contents, the BI controls, the sterilizer’s history, and the facility’s validated response procedure.

Immediate actions after a positive result

1. Place the sterilizer on hold

Remove the sterilizer from routine service pending investigation. Notify the appropriate supervisor, infection prevention personnel, quality representative, and—when indicated—sterilizer maintenance or biomedical engineering. CDC’s suggested protocol begins by taking the sterilizer out of service and notifying responsible oversight functions. [2]

Do not release a load solely because its external process indicator changed or because the cycle display reported completion. These observations can support the investigation, but they do not replace the facility’s BI response process.

2. Identify potentially affected loads

Determine which load produced the positive BI and identify all items processed since the last acceptable negative BI, according to the facility’s traceability system. Preserve the associated records rather than overwriting, discarding, or correcting them retrospectively.

At minimum, link the investigation to:

• sterilizer identification and cycle number;
• date and time of the cycle;
• operator and department;
• load description and configuration;
• cycle printout or electronic parameters;
• BI lot, expiration date, location, and result;
• positive-control result;
• chemical indicator results;
• maintenance, repair, calibration, and utility records; and
• distribution or patient-use information, where applicable.

FDA emphasizes reviewing process-control and monitoring records, acceptance activities, equipment status, and recent device-history records when assessing sterilization control. [1]

Differentiate a process failure from a test failure

Before concluding that the sterilizer failed, verify that the BI was suitable for the process and was handled correctly. Review storage conditions, lot information, expiration status, incubation conditions, reader operation, and interpretation criteria. Confirm that the positive control behaved as expected and that the test was not compromised by labeling, transport, incubation, or documentation errors.

The BI manufacturer’s instructions should be followed for activation, incubation, readout, and interpretation. A positive test-control result may indicate a viable and responsive indicator population, whereas an invalid or failed control can make the test inconclusive rather than positive in the usual sense.

The chemical indicator and physical record should also be reviewed. A satisfactory chemical indicator does not invalidate a positive BI, and a normal-looking cycle display does not prove that the BI result is erroneous. FDA identifies chemical indicators, biological indicators, and process-record review as complementary elements of sterilization monitoring rather than interchangeable tests. [1][3]

Repeat testing and equipment investigation

For a steam sterilizer, CDC’s suggested protocol recommends repeating BI testing in three consecutive cycles after a single positive spore test, while investigating whether the sterilizer or procedure was defective. If additional BIs remain positive, items processed since the last acceptable negative BI should be considered potentially nonsterile and recalled or reprocessed according to the facility’s procedure. [2]

Repeat testing should not be used as a substitute for investigating the original event. Review whether:

• the correct cycle was selected;
• the load was arranged as validated or instructed;
• packages or containers exceeded loading limits;
• the BI or process challenge device was positioned appropriately;
• the sterilizer reached the required validated conditions;
• air removal, exposure, drying, or other cycle phases showed abnormalities;
• the steam supply or facility utilities changed; and
• recent maintenance, repairs, software changes, or calibration issues occurred.

CDC specifically identifies incorrect time or temperature settings, steam-supply abnormalities, equipment irregularities, incorrect BI selection, and interpretation problems as issues to check during the response. [2]

When recall or reprocessing may be necessary

The scope of a recall should be based on evidence and the facility’s risk-management procedure. A single positive BI in a steam sterilizer does not automatically mean that every item processed must be recalled; CDC states that nonimplantable items do not necessarily require recall after a single positive spore test unless the sterilizer or procedure is defective. [2]

However, if repeat tests remain positive, if a cycle or equipment defect is identified, or if the affected load cannot be shown to have met the validated process requirements, the items should be treated as suspect. The organization should identify, segregate, recall, and reprocess affected supplies as appropriate. Implantable devices generally warrant more conservative handling because they may have been used before BI results were available; facility policy should address quarantine and release requirements for these loads.

Recall decisions should be documented with the reason for the decision, the population of affected loads, the date range, the disposition of items, and the person authorizing release or reprocessing.

Documentation that supports a defensible decision

A useful investigation record should show the sequence of events rather than only the final conclusion. Include the original BI result, control results, cycle data, load details, interviews or operator statements, equipment findings, repeat BI results, corrective actions, and final disposition.

Where a facility uses electronic traceability, the sterilizer cycle identifier should be linked to the load contents and downstream distribution records. Where paper records are used, the same links should be created through consistent load numbers, operator initials, and documented review. FDA’s inspection guidance underscores the importance of reviewing records across recent runs and shifts, not merely examining a single isolated cycle. [1]

Corrective and preventive actions

Once the immediate risk is controlled, assess whether corrective action should address training, loading practices, BI handling, equipment maintenance, steam quality, documentation, or procedure design. A recurring positive BI may reflect a systemic problem even when individual operators appear to have followed instructions.

Trend BI events, aborted cycles, failed chemical indicators, wet loads, packaging damage, and maintenance findings together. This broader view may reveal patterns that are not visible when each event is investigated separately.

Limitations

Published guidance does not replace a validated sterilization process or a site-specific failure-response procedure. The CDC protocol cited here is a suggested approach for steam sterilizers and may not apply unchanged to ethylene oxide, vaporized hydrogen peroxide, radiation, liquid chemical processes, or specialized pharmaceutical and medical-device manufacturing settings. BI behavior, incubation time, reader technology, and release procedures depend on the specific indicator and process.

Practical takeaway

The safest response to a positive BI is neither automatic reassurance nor automatic recall of every item. Place the sterilizer on hold, preserve traceability, verify the test and controls, review the cycle and load, investigate equipment and utilities, perform the required repeat testing, and document the evidence supporting the final disposition.

Educational disclaimer: This article provides general educational information for sterilization and quality professionals. It is not a substitute for applicable regulations, validated procedures, manufacturer instructions, competent technical assessment, or facility-specific infection prevention and recall policies.

References

1. U.S. Food and Drug Administration. Sterilization Process Controls. FDA inspection guidance.
2. Centers for Disease Control and Prevention. Table 12: Suggested protocol for management of positive biological indicator in a steam sterilizer.
3. U.S. Food and Drug Administration. Premarket Notification [510(k)] Submissions for Chemical Indicators: Guidance for Industry and FDA Staff.
4. U.S. Food and Drug Administration. Recognized Consensus Standards: Medical Devices—including biological-indicator guidance and moist-heat sterilization standards.

References

1. Sterilization Process Controls. U.S. Food and Drug Administration. 2022-03-31.
2. Table 12: Suggested protocol for management of positive biological indicator in a steam sterilizer. Centers for Disease Control and Prevention. 2023-12-20.
3. Premarket Notification [510(k)] Submissions for Chemical Indicators: Guidance for Industry and FDA Staff. U.S. Food and Drug Administration. 2002-09-04.
4. Recognized Consensus Standards: Medical Devices. U.S. Food and Drug Administration. 2026-05-25.

Educational overview. Follow the applicable product instructions, validated procedures, local regulations and your facility’s approved policies.